IPHA WELCOMES POSITIVE TREND IN CANCER SURVIVAL

IPHA WELCOMES POSITIVE TREND IN CANCER SURVIVAL

 

BUT IRELAND IS SLOW AND LATE IN MAKING NEW CANCER MEDICINES AVAILABLE

                                                                                                                                                                   

IMPROVING SPEED OF ACCESS TO NEW CANCER MEDICINES AN URGENT PRIORITY

 

Tuesday 7th November, 2017

 

The Irish Pharmaceutical Healthcare Association (IPHA), which represents 47-research based pharmaceutical companies in Ireland, has warmly welcomed the latest National Cancer Registry Annual Report. 

 

Oliver O’Connor, IPHA Chief Executive, said:  “It is very encouraging that the Report shows that almost 170,000 people in Ireland have survived after getting a diagnosis of cancer, equivalent to 3.6% of the Irish population. 

“These positive developments owe much to the impact of new cancer medicines that have been developed with very large research and development investment by industry.  The pharmaceutical industry is committed to continuing this high level of investment and research.

“To sustain continue improved outcomes for patients, new cancer medicines must be made available quickly in our health services.  Unfortunately, Ireland has fallen behind in recent years in this respect. 

 

Independent data from Quintiles IMS has shown that only one-fifth of new cancer drugs launched internationally in 2014-15 were available in Ireland in 2016.  Ireland performs worst amongst our peer group of Western European countries by this measure.  Prices and spending on medicines in Ireland are at the average of the 14 EU countries but availability of new medicines is slowest. 

 

O’Connor said,

“If we is to achieve the goal of the Government’s new Cancer Strategy of achieving cancer survival rates among the top quartile in Europe, we will need to make new cancer medicines available as quickly as in the top quartile in Europe”.

 

“We have to take a hard look at our approval processes and Exchequer funding decisions to achieve this.  As Professor Francesco Pignatti, head of oncology at the European Medicines Agency, said recently, “Science and standards are here to serve patients and not the other way round”.

 

Contact Philip Hannon on 087 2870891

 

 

IPHA is a member of -

AESGPEFPIA

For medicines and clinical trials information visit -

medicines.ieself-care.ieICTRP Portal